Get the Stockscreener App
36.25
2.37%
0.84
After Hours:
36.10
-0.15
-0.41%
Arrowhead Pharmaceuticals Inc stock is traded at $36.25, with a volume of 1.56M.
It is up +2.37% in the last 24 hours and up +21.97% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$35.41
Open:
$35.67
24h Volume:
1.56M
Relative Volume:
0.65
Market Cap:
$5.01B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-26.08
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
-3.33%
1M Performance:
+21.97%
6M Performance:
+207.46%
1Y Performance:
+96.58%
1-Day Range:
$35.50
$37.07
1-Week Range:
$34.91
$37.87
52-Week Range:
$9.57
$39.42
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
36.25 | 4.90B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Advanced analytics toolkit walkthrough for Arrowhead Pharmaceuticals Inc.July 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Sector ETF performance correlation with Arrowhead Pharmaceuticals Inc.2025 Risk Factors & Low Risk High Reward Ideas - newser.com
Applying Wyckoff theory to Arrowhead Pharmaceuticals Inc. stock2025 Market Sentiment & Free Safe Entry Trade Signal Reports - newser.com
How buybacks impact Arrowhead Pharmaceuticals Inc. stock valueJuly 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
Is Arrowhead Pharmaceuticals Inc. showing signs of accumulationOil Prices & Verified Swing Trading Watchlist - newser.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Arrowhead Pharmaceuticals Inc a good long term investmentSector Performance Review & Free Double Digit Growth Tips - earlytimes.in
Arrowhead Pharmaceuticals Inc HDP1 Stock Analysis and ForecastMACD Histogram Signals & Budget Friendly Capital Growth - earlytimes.in
Short interest data insights for Arrowhead Pharmaceuticals Inc.July 2025 Snapshot & Free Real-Time Market Sentiment Alerts - newser.com
Arrowhead Pharmaceuticals Inc. stock chart pattern explainedEarnings Recap Summary & Community Supported Trade Ideas - newser.com
Pinion Investment Advisors LLC Has $1.19 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Will Arrowhead Pharmaceuticals Inc. see short term momentum2025 Price Targets & Daily Market Momentum Tracking - newser.com
What Fibonacci levels say about Arrowhead Pharmaceuticals Inc. reboundLong Setup & Fast Momentum Entry Tips - newser.com
Has Arrowhead Pharmaceuticals Inc. found a price floorJuly 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com
Can Arrowhead Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
What to expect from Arrowhead Pharmaceuticals Inc. in the next 30 daysCPI Data & Stock Portfolio Risk Management - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Is Arrowhead Pharmaceuticals Inc. still worth holding after the dipM&A Rumor & Consistent Growth Stock Picks - newser.com
What technical models suggest about Arrowhead Pharmaceuticals Inc.’s comebackM&A Rumor & Low Volatility Stock Suggestions - newser.com
Arrowhead Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC Wainwright - MarketBeat
RBC Raises Price Target on Arrowhead Pharmaceuticals to $45 From $38, Keeps Outperform, Speculative Risk - MarketScreener
HC Wainwright & Co. Reiterates Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
Arrowhead Pharma (ARWR) Analyst Rating Update: HC Wainwright & C - GuruFocus
Arrowhead Pharmaceuticals Hits New 52-Week High of $39.42 - Markets Mojo
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - BioSpace
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNA - PharmiWeb.com
Arrowhead Pharmaceuticals Hits New 52-Week High of $36.24 - Markets Mojo
RNAi: The Benefits Of Shooting The Messenger - Seeking Alpha
Arrowhead Pharmaceuticals And Wave Life Sciences: RNAi Is Getting Into Obesity (NASDAQ:WVE) - Seeking Alpha
Arrowhead Pharmaceuticals files CTA for investigational Aro-Dimer-PA - MarketScreener
Arrowhead files for approval of dual-target RNAi therapy for heart disease - Investing.com Nigeria
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You - simplywall.st
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 12-Month HighStill a Buy? - MarketBeat
Will Arrowhead Pharmaceuticals Inc. stock outperform Dow Jones indexJuly 2025 Price Swings & Verified Entry Point Signals - newser.com
Tools to monitor Arrowhead Pharmaceuticals Inc. recovery probabilityEarnings Miss & AI Driven Stock Price Forecasts - newser.com
Insider Sell: James Hamilton Sells 20,000 Shares of Arrowhead Ph - GuruFocus
Future of RNAi Therapeutics: Small Interfering RNAs, - openPR.com
BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $42 - 富途牛牛
Custom strategy builders for tracking Arrowhead Pharmaceuticals Inc.2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock outperform small cap peersJuly 2025 Market Mood & Safe Entry Momentum Tips - newser.com
Ranking Arrowhead Pharmaceuticals Inc. among high performing stocks via toolsWeekly Trend Recap & Real-Time Stock Entry Alerts - newser.com
Why millennials buy Arrowhead Pharmaceuticals Inc. (HDP1) stock2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):